Our
Ambition

EvolveImmune Therapeutics is pioneering a new class of precision cancer medicines to deliver superior patient outcomes compared to current anti-cancer therapies. 

We have validated new pathways which are essential to overcome CD8 T cell exhaustion in the tumor microenvironment. Our therapeutic ambition is to selectively regulate these mechanisms to drive effective, durable anti-cancer immunity, to transform the lives of cancer patients and their loved ones.